Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Persistent or recurrent disease ≤ 24 months of last BCG dose, but not classified as BCG unresponsive~* Histologically confirmed persistent or recurrent high-risk non-muscle-invasive urothelial carcinoma (UC)~* Treated with at least 1 adequate course of induction BCG therapy (at least 5 out of 6 doses)~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2~Exclusion Criteria:~* Previous or concurrent muscle invasive, locally advanced, or disseminated/metastatic UC~* UC in the upper genitourinary tract (kidneys, renal collecting systems, ureters) within 24 months of enrollment~* UC and/or CIS in the prostatic urethra within 12 months of enrollment~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: nivolumab + Bacillus Calmette-Guérin (BCG) (Type: EXPERIMENTAL): None
- Arm B: placebo +BCG (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).